Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
A Study of GSK5764227 in Participants With Advanced Solid Tumors
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 281
- Registration Number
- NCT06551142
- Locations
- 🇬🇧
GSK Investigational Site, Edinburgh, United Kingdom
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
- Conditions
- Metastatic Biliary Tract Cancer
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT06548412
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Chemoimmunotherapy Combined with Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
- Conditions
- Biliary Tract CancerCholangiocarcinoma
- Interventions
- Radiation: Spatially Fractionated RTDevice: Deep Hyperthermia
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 15
- Registration Number
- NCT06546969
- Locations
- 🇺🇸
Maryland Proton Treatment Center, Baltimore, Maryland, United States
🇺🇸University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
- Conditions
- Cervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Squamous Cell CarcinomaStage IVB Cervical Cancer American Joint Committee on Cancer (AJCC) v8
- Interventions
- Procedure: Biospecimen CollectionRadiation: BrachytherapyRadiation: External Beam Radiation TherapyOther: Questionnaire Administration
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT06543576
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California San Diego (UCSD), San Diego, California, United States
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- The National Center of Oncology, Azerbaijan
- Target Recruit Count
- 200
- Registration Number
- NCT06531447
- Locations
- 🇦🇿
Elchin Mansurov, Baku, Azerbaijan
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Head and Neck Squamous Cell CarcinomaHypopharyngeal Squamous Cell CarcinomaLaryngeal Squamous Cell CarcinomaNasopharyngeal Squamous Cell CarcinomaOral Cavity Squamous Cell CarcinomaOropharyngeal Squamous Cell CarcinomaStage 0 Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Interventions
- Other: Best PracticeProcedure: Biospecimen CollectionProcedure: Computed TomographyRadiation: Image Guided Radiation TherapyRadiation: Intensity-Modulated Radiation TherapyProcedure: Magnetic Resonance ImagingDrug: Placebo AdministrationDrug: MnSOD Mimetic BMX-001Other: Questionnaire Administration
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 98
- Registration Number
- NCT06532279
Effect of HIPEC After Radical Surgery on Long-term Survival for Locally Advanced Gastric Cancer
- Conditions
- Gastric CancerSurvival Rate
- Interventions
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 302
- Registration Number
- NCT06525714
Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Drug: BEBT-109 Capsules
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- BeBetter Med Inc
- Target Recruit Count
- 30
- Registration Number
- NCT06514027
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 143
- Registration Number
- NCT06510465
- Locations
- 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
🇨🇳Renji Hospital, Shanghai, China
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
- Conditions
- Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 52
- Registration Number
- NCT06501625
- Locations
- 🇺🇸
Northwestern Medicine, Chicago, Illinois, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Gibbs Cancer Center, Spartanburg, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.